期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

曲妥珠单抗耐药机制及对策研究进展

Mechanism of action,resistance and therapeutic strategies of trastuzumab
原文传递
导出
摘要 曲妥珠单抗是靶向人表皮生长因子2(c-erbB-2,HER2)的单克隆抗体,治疗HER2阳性乳腺癌疗效确切,然而其客观反应率并不高,而且多数患者在1年内出现获得性耐药。目前的基础研究初步解释了曲妥珠单抗耐药的分子机制,一些新的治疗策略为曲妥珠单抗耐药患者带来新的希望。本文综述了近年来有关曲妥珠单抗的耐药机制及其应对策略的研究进展。 Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 （ HER2 ）. Trastuzumab has shown clinical activity in HER2-positive breast cancers. However, the patient objective response rates to trastuzumab monotherapy were low and the majority of patients with metastatic breast cancer demonstrated disease progression within 1 year after treatment initiation. Preclinical studies have indicated several molecular mechanisms that could contribute to the development of trastuzumab resistance. Novel therapies offer hope for patients with trastuzumab resistance.
作者 李晓玲 徐建明 宋三泰
机构地区 军事医学科学院附属医院肿瘤中心
出处 《军事医学科学院院刊》 CSCD 北大核心 2008年第4期392-394,共3页 Bulletin of the Academy of Military Medical Sciences
关键词 曲妥珠单抗 HER2 耐药 trastuzumab HER2 resistance
分类号 R737.9 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献12

  • 1Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer[J]. Nat Clin Pract Oncol, 2006, 3(5) : 269 -280.
  • 2Anastasi S, Sala G, Huiping C, et al. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin [ J ]. Oncogene, 2005, 24 (28) : 4540 - 4548.
  • 3Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells[J]. CancerRes, 2005, 65(23) :11118 -11128.
  • 4Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line[J]. Cancer Res, 2005, 65(2) : 473 -482.
  • 5Wang SE,Narasanna A, Perez-Torres M, et al. HEP,2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors [J]. Cancer Cell,2006,10 ( 1 ) :25 - 38.
  • 6Kute T, Lack CM, Willingham M, et al. Development of Herceptin resistance in breast cancer cells[J].Cytometry A, 2004, 57(2) : 86 -93.
  • 7Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer[J]. Arm Oncol, 2007, 18(6) : 977 -984.
  • 8Allen LF, Lenehan PF, Eiseman IA,et al. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer[J]. Semin Oncol, 2002, 29 (3 Suppl 11) :11 -21.
  • 9Chan S, Seheulen ME, Johnston S,et al. Phase Ⅱ study of temsirolimus (CCI-779) ,a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [ J ]. J Clin Oncol,2005,23 (23) :5314 -5322.
  • 10Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP- 751,871 [J]. Clin Cancer Res,2005,11 (5) :2063 -2073.
军事医学科学院院刊
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部